Advantages of MelArray over Oncomine Focus Assay for Mutation Analysis in Melanoma
Andrew E. Quacoe, Sandra N. Freiberger, Mitchell P. Levesque, Reinhard Dummer, Egle Ramelyte
TL;DR
This study compares two DNA sequencing tests for melanoma and finds that one test, MelArray, detects more mutations that could guide personalized cancer treatments.
Contribution
The study demonstrates that MelArray, a melanoma-specific test, identifies more relevant mutations than a generic cancer test, aiding personalized therapy.
Findings
MelArray detected more mutations in TERT promoter and CDKN2A genes compared to Oncomine Focus Assay.
BRAF mutations were common across melanoma subtypes but not linked to specific tumor features.
MelArray provides genome-wide analysis and tumor mutational burden assessment, offering broader insights.
Abstract
Background and Objectives: Melanoma is the leading cause of skin cancer-related mortality due to its high propensity for early metastasis, although survival rates have improved with the advent of targeted and immune-based therapies. Accurate detection of targetable mutations and assessment of tumor mutational burden are essential for informed therapeutic decision-making. Mutation profiling is routinely performed using next-generation sequencing (NGS). The Oncomine Focus Assay (OFA) detects common alterations in 52 genes across various tumor entities, whereas MelArray is a melanoma-specific NGS panel covering mutations in 190 melanoma-relevant genes and providing a genome-wide copy number analysis. Moreover, tumor mutational burden is being assessed. Materials and Methods: In this retrospective study, we analyzed the phenotypic characteristics of 100 patients with cutaneous melanoma who…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
Figure 12
Figure 13Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCutaneous Melanoma Detection and Management · Melanoma and MAPK Pathways · melanin and skin pigmentation